[Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients – Montreal Heart Insititute

Study Protocol: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19) – ClinicalTrials.gov

“Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days.”

Commentaries: ‘Major breakthrough’ | Large study shows effectiveness of colchicine to treat COVID-19 – The Canadian AND A gout drug shows promise for Covid-19, but skeptics worry about trusting science by press release – STAT

Commentary on Twitter

Press release ? #colchicine decreased ⬇️
? hospitalizations 25%
? use of ventilation 50%
? mortality 44%
in multinational trial of >4,000 non-hospitalized #COVID patients

More: https://t.co/htMRdParq3

Full report awaited…@EricTopol @DrEricDing @MartinLandray #EBM pic.twitter.com/iodiEJBtV1

— Kari Tikkinen (@KariTikkinen) January 23, 2021